Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.15.6407

Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer  

Yuksel, Ozgur Haki (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital)
Urkmez, Ahmet (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital)
Akan, Serkan (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital)
Yldirim, Caglar (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital)
Verit, Ayhan (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.15, 2015 , pp. 6407-6412 More about this Journal
Abstract
Purpose: To predict prostatic carcinoma using a logistic regression model on prebiopsy peripheral blood samples. Materials and Methods: Data of a total of 873 patients who consulted Urology Outpatient Clinics of Fatih Sultan Mehmet Training and Research Hospital between February 2008 and April 2014 scheduled for prostate biopsy were screened retrospectively. PSA levels, prostate volumes, prebiopsy whole blood cell counts, neutrophil and platelet counts, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), biopsy results and Gleason scores in patients who had established diagnosis of prostate cancer (PCa) were evaluated. Results: This study was performed on a total of 873 cases, with an age range 48-76 years, divided into three groups as for biopsy results. with diagnoses of benign prostatic hyperplasia (BPH) (n=304, 34.8 %), PCa (n=265, 30.4 %) and histological prostatitis (n=304; 34.8 %). Intra- and intergroup comparative evaluations were performed. White blood cell and neutrophil counts in the histological prostatitis group were significantly higher than those of the BPH and PCa groups (p=0.001; p=0.004; p<0.01). A statistically significant intergroup difference was found for PLR (p=0.041; p<0.05) but not lymphocyte count (p>0.05). According to pairwise comparisons, PLR were significantly higher in the PCa group relative to BPH group (p=0.018, p<0.05, respectively). Though not statistically significant, higher PLR in cases with PCa in comparison with the prostatitis group was remarkable (p=0.067, and p>0.05, respectively). Conclusions: Meta-analyses showed that in patients with PSA levels over 4 ng/ml, positive predictive value of PSA is only 25 percent. Therefore, novel markers which can both detect clinically significant prostate cancer, and also prevent unnecessary biopsies are needed. Relevant to this issue in addition to PSA density, velocity, and PCA3, various markers have been analyzed. In the present study, PLR were found to be the additional predictor of prostatic carcinoma.
Keywords
Prostatic carcinoma; PSA; platelet-to-lymphocyte ratio; neutrophil-to-lymphocyte ratio;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Sonpavde G, Pond GR, Armstrong AJ, et al (2014). Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer, 12, 317-4.   DOI
2 Sumbul AT, Sezer A, Abali H, et al (2014). Neutrophil-tolymphocyte ratio predicts PSA response, but notoutcomes in patients with castration-resistant prostate cancer treated withdocetaxel. Int Urol Nephrol, 46, 1531-5.   DOI
3 Tai CG, Johnson TV, Abbasi A, et al (2014). External validation of the modified glasgow prognostic score for renal cancer. Indian J Urol, 30, 33-7.   DOI
4 Tanik S, Albayrak S, Zengin K, et al (2014). Is the neutrophillymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev, 15, 6375-9.   DOI
5 Templeton AJ, Pezaro C, Omlin A, et al (2014). Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer, 120, 3346-2.   DOI
6 Fujita K, Hosomi M, Nakagawa M, et al (2014). White blood cell count is positively associated with benign prostatic hyperplasia. Int J Urol, 21, 308-2.   DOI
7 Fujita K, Imamura R, Tanigawa G, et al (2012). Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis, 15, 386-0.   DOI   ScienceOn
8 Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia (2009). Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an innercity population. Int J Gynecol Cancer, 19, 1384-9.   DOI
9 Gueron G, De Siervi A, Vazquez E (2012). Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis, 15, 213-1   DOI
10 Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009). The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet, 279, 53-6.   DOI
11 Jarnicki A, Putoczki T, Ernst M (2010). Stat3: linking inflammation to epithelial cancer more than a "gut" feeling? Cell Div, 5, 14.   DOI   ScienceOn
12 Kantoff PW, Higano CS, Shore ND, et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411-2.   DOI
13 Kramer G, Mitteregger D, Marberger M (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol, 51, 1202-6.   DOI
14 Karazanashvili G (2008). Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol, 54, 1383-4.   DOI
15 Keizman D, Gottfried M, Ish-Shalom M, et al (2012). Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistantprostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist, 17, 1508-4.   DOI
16 Kerpsack JT, Finan MA (2000). Thrombocytosis as a predictor of malignancy in women with a pelvic mass. J Reprod Med, 45, 929-2.
17 Li AJ, Madden AC, Cass I, et al (2004). The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol, 92, 211-4.   DOI
18 Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-4.   DOI
19 McDonald AC, Vira MA, Vidal AC, et al (2014). Association between systemic inflammatory markers and serum prostatespecific antigen in men without prostatic disease - the 2001-2008 national health and nutrition examination survey. Prostate, 74, 561-7.   DOI
20 Mengus C, Le Magnen C, Trella E, et al (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med, 9, 162.   DOI
21 Mistry K, Cable G (2003). Meta-analysis of prostatespecific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract, 16, 95-1.   DOI
22 Prins RC, Rademacher BL, Mongoue-Tchokote S, et al (2012). C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol, 30, 33-7.   DOI   ScienceOn
23 Nuhn P, Vaghasia AM, Goyal J, et al (2013). Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castrationresistantprostate cancer (mCRPC) treated with first-line docetaxel. BJU Int, e-pub ahead of print, doi: 10.1111/bju.12531.   DOI
24 Palapattu GS, Sutcliffe S, Bastian PJ, et al (2005). Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 26, 1170-1.
25 Pond GR, Armstrong AJ, Wood BA, et al (2012). Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int, 110, 461-8.   DOI   ScienceOn
26 Roehl KA, Antenor JA, Catalona WJ (2002). Serial biopsy results in prostate cancer screening study. J Urol, 167, 2435-9.   DOI
27 Schaider H, Oka M, Bogenrieder T, et al (2003). Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer, 103, 335-3.   DOI
28 Shafique K, Proctor MJ, McMillan DC, et al (2012). Systemic inflammation and survival of patients with prostate cancer: evidence from the glasgow inflammation outcome study. Prostate Cancer Prostatic Dis, 15, 195-1.   DOI
29 Shafique K, Proctor MJ, McMillan DC, et al (2013). The modified glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer, 13, 292.   DOI